Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a phase 2 study of nipocalimab for early-onset severe hemolytic disease of the fetus and newborn, 54% of high-risk pregnancies resulted in live births at or after 32 weeks’ gestation without intrauterine transfusions, compared to a historical benchmark of 0%.
Hematology August 20th 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH